carcinoma and benign prostatic hyperplasia (BPH), and to compare the prevalence and types of atrophy between two investigated groups. Methods: Histologic analysis of 1096 slides from 50 patients with carcinoma and 277 slides from 31 patients with BPH was performed to evaluate, according to the new prostatic atrophy classification, the number of foci and type of atrophic lesions. Results: Age, Gleason grade, and TNM showed no significant correlation with the number of proliferative atrophy (PA) and proliferative inflammatory atrophy (PIA) foci (p > 0.05). PIA was significantly more frequent in prostates with carcinoma (1.63 vs 1.27 atrophic lesions per slide) (p < 0.001), whereas PA displayed an increased frequency in BPH (2.28 vs 0.76 atrophic lesions per slide) (p < 0.001). Conclusions: We confirmed that PA and PIA are common findings in prostates with and without carcinoma, but the question of whether inflammation produces tissue damage and PA or whether some other insult induces the tissue damage and atrophy directly, with inflammation occurring secondarily, is still unresolved.
Editorial Comment
In this study, the authors found that patients with benign prostatic hyperplasia (BPH) had a significantly higher number of prostatic atrophy foci compared with patients with carcinoma. On the other hand, in patients with carcinoma, inflammatory prostatic atrophy was more prevalent compared with prostatic atrophy without inflammation, and slides from these patients contained a significantly higher number of inflammatory prostatic atrophy foci compared with slides from BPH patients. The authors recognize that slides with carcinoma contained peripheral and transitional zones, whereas slides with BPH were mainly composed of transitional zones. Thus, the obtained different prevalence of atrophy in malignant and benign cases could partially reflect the difference in distribution between various anatomic compartments of the prostate.
In a study on autopsies, we found inflammatory atrophy in 66% and atrophy without inflammation in 22% of analyzed cases (1). We did not find any association between the presence of inflammatory atrophy and the likelihood of cancer, and no topographic association between atrophy and prostate cancer foci as well as high-grade prostatic intraepithelial neoplasia (PIN).
The link between atrophy and /or inflammatory atrophy and prostate cancer is theoretically attractive but controversial (1) (2) (3) (4) (5) (6) (7) (8) . It has been difficult to verify a clinical connection between the lesions. A recent report associating extension of prostatic atrophy to serum PSA elevation added a novel interest to this intriguing lesion (9,10). disease progression was suggested by unfavorable follow-up needle biopsy findings based on extension of the tumor and Gleason grading.
The pathology report has a decisive importance for the selection of patients for expectant management. In patients with stage T1c prostate cancer and prostate-specific antigen (PSA) < 0.15 ng/mL, the biopsy should not show Gleason pattern 4 or 5, greater than 2 biopsy cores with cancer or greater than 50% involvement of any core. Patients that fulfill these criteria have a 79.9% probability for harboring insignificant tumors (less than 0.5 cm 3 ) (2). Insignificant, however, does not mean latent (dorment or indolent) tumor. It means a small volume tumor with favorable pathological findings: low-grade Gleason score, confined to the prostate and no positive surgical margins. Unfortunately, so far there is no marker for the biological behavior of prostate cancer.
